Released on = November 16, 2006, 12:29 am

Press Release Author = Olivia Andrews

Industry = Pharmaceuticals

Press Release Summary = Tramadol Ultram has played a major role in the treatment of
different sort of pains ranging from acute too chronic pain.

Press Release Body = A large number of people suffer from different sort of pains
either acute to moderate to severe pain and almost 50 million Americans suffer from
chronic pain. FDA has also approved Ultram in September 2005 based upon a safety and
clinical data after undergoing clinical trials.

Seizures have been reported in patients receiving tramadol. The risk of seizure is
increased with doses of tramadol above the recommended range and in patients taking
certain medications such as tricyclic antidepressants, selective serotonin reuptake
inhibitors, or opioids. Administration of tramadol may enhance the seizure risk in
patients taking MAO inhibitors, neuroleptics, other drugs that reduce the seizure
threshold, or in patients with epilepsy, those with a history of seizures, or in
patients with a recognized risk for seizure (such as head trauma, metabolic
disorders, alcohol and drug withdrawal, CNS infections).

\"Chronic pain affects a large segment of the U.S. population, with an estimated 45
percent of all Americans seeking care for persistent pain at least once during their
lifetime,\" according to Dr. Fernandes

The development of a once-daily formulation of tramadol is indicative of how an
innovative drug-delivery technology can overcome the most difficult formulation
enhancement challenges,\" said Douglas.

Tramadol, like other opioids used in analgesia, can be abused. ULTRAM should not be
used in patients who are suicidal or addiction-prone, or taken with
alcohol-containing beverages.

For more information, visit our website http://www.benzer11.com/ultram.html to know
about approved medicines and treatments.



Web Site = http://www.benzer11.com

Contact Details = Binghamton, NY 13902
email: webmaster@benzer11.com